Introduction
Job descriptions for regulatory affairs roles tend to emphasize the run-up to approval: compiling a submission, responding to agency questions, tracking a review clock. That work is real and it matters, but it is not where the job ends. A surprising share of a regulatory professional's career, especially past the first few years, is spent on products that are already on the market. Understanding what that work looks like is useful whether you are choosing a specialization, preparing for an interview, or just trying to picture what the day-to-day is like once the excitement of a launch fades.
The Approval Is a Milestone, Not an End Point
An approval, clearance, or CE mark closes one phase of a product's regulatory life and opens another. From the moment a product reaches patients or users, the regulatory obligations shift from proving safety and efficacy on paper to confirming it in practice. Agencies expect manufacturers to keep watching, keep reporting, and keep updating their files as real-world evidence accumulates. For a regulatory affairs professional, this means the file you helped build during development becomes a living document you maintain for as long as the product is sold, and often for a defined period after it is withdrawn.
This is a genuine shift in mindset for people who came up focused on getting to yes. Post-market work rewards different skills: pattern recognition across incoming reports, comfort with ambiguity when a signal is not yet a confirmed problem, and the discipline to keep documentation current when there is no external deadline forcing your hand. It also requires learning to read a product's regulatory file the way you would read a patient's chart: not as a one-time deliverable, but as a running record that has to stay accurate for years, sometimes decades, after the original approval date.
Post-Market Surveillance and Vigilance Reporting
Every marketed drug, biologic, and device is subject to some form of ongoing surveillance. For pharmaceuticals, this includes adverse event collection and expedited reporting to health authorities when a serious, unexpected reaction is identified. For medical devices, MDR and IVDR in the European Union impose explicit post-market surveillance plans, and FDA maintains its own vigilance and medical device reporting requirements. Regulatory affairs professionals working in this space are often the bridge between the safety or quality function that first identifies a signal and the regulatory submission that formally reports it to an authority within a required timeframe.
The work is procedural but not mechanical. Deciding whether an event meets the threshold for expedited reporting, whether a trend constitutes a new signal, and how to phrase a report so it is accurate without overstating or understating risk all require judgment. Missing a reporting deadline, or filing a report that misrepresents the underlying data, carries real consequences for the company and, more importantly, for patients relying on that surveillance system to catch problems early. In practice, this often means building relationships with the pharmacovigilance or complaint-handling teams who see raw reports first, since the quality of a vigilance filing depends heavily on how quickly and clearly that underlying information reaches regulatory.
Periodic Reporting and Renewals
Beyond event-driven reporting, most marketed products carry periodic obligations regardless of whether anything has gone wrong. Periodic Safety Update Reports in the EU, annual reports to FDA for approved drugs, and periodic post-market surveillance reports under MDR are examples of scheduled documentation that aggregates safety and performance data over a defined window. Licenses, registrations, and certifications also expire and need renewal, sometimes on a rolling multi-year cycle across dozens of countries for a single product.
This is where a career in post-market regulatory affairs starts to look less like firefighting and more like portfolio management. Professionals in this space often track dozens of products across multiple markets, each with its own renewal calendar and reporting cadence. It is detail-intensive work, and companies with global product lines rely heavily on people who can keep that calendar straight without letting anything lapse. A lapsed registration is rarely dramatic in the moment, nothing breaks visibly, but it can quietly halt the ability to sell a product in a given market until it is corrected, which makes this unglamorous tracking work more consequential than it looks from the outside.
Managing Change: Variations, Supplements, and Labeling Updates
Products rarely stay static after launch. Manufacturing processes get optimized, suppliers change, new safety information prompts a label update, or a company wants to extend a product into a new population or indication. Each of these changes typically requires regulatory review before it can be implemented, whether that means a formal supplement to FDA, a variation to a European marketing authorization, or a simple notification depending on the significance of the change.
Classifying a proposed change correctly, that is, understanding whether it needs prior approval or can be reported after the fact, is a skill that takes real experience to build. Get it wrong in one direction and you delay a beneficial change unnecessarily; get it wrong in the other and you risk implementing something the authority needed to review first. Regulatory professionals in this role often work closely with manufacturing, quality, and commercial teams who want changes made quickly, while holding the line on what the regulatory pathway actually requires. Over time, the professionals who handle this well build an internal reputation as people who can move things forward efficiently rather than people who simply say no, which is a meaningfully different position to hold inside a company.
Advertising and Promotional Review
Once a product is approved, marketing wants to talk about it, and in most jurisdictions there are rules about how. Regulatory affairs professionals frequently sit on promotional review committees, checking that advertising claims are consistent with the approved labeling, that comparative claims are substantiated, and that materials meet the specific disclosure requirements of each market. This is a different kind of scrutiny than a submission review, it moves fast, cycles constantly as campaigns are refreshed, and requires a working fluency in both the regulatory file and the commercial team's goals.
When Something Goes Wrong: Recalls and Field Corrective Actions
Not every post-market story is routine. When a quality or safety issue is serious enough, it can trigger a recall or a field corrective action, and regulatory affairs is typically involved in classifying the severity of the issue, notifying the relevant authorities within required timeframes, and coordinating the communication that goes out to affected customers or patients. This is high-pressure work with real stakes, and it tends to draw on everything a regulatory professional has learned about a product, since a recall decision often has to be made with incomplete information under time pressure.
How the Work Differs by Company Size
At a large, established company with dozens of marketed products, post-market regulatory affairs is usually its own dedicated function with specialists focused narrowly on vigilance, others on labeling and change control, and others on renewals and registrations. The scale allows for real specialization, and it also means a newer team member can build deep expertise in one piece of the lifecycle before being expected to own the whole picture.
At a smaller company with one or two marketed products, the same person who worked the original approval often continues to own that product's regulatory life indefinitely, handling surveillance, renewals, and change control alongside whatever new development work is also underway. This version of the role demands more breadth and less depth early on, but it also gives a much faster, more complete view of how a product's entire regulatory story fits together, which some professionals find is the better way to learn the function.
Where This Work Sits in a Career
Post-market regulatory affairs is sometimes treated as a less glamorous specialty than working on new submissions, but that reputation undersells it. It builds a genuinely different and valuable skill set: signal detection, cross-functional coordination under time pressure, and a granular understanding of how a product actually performs once it leaves the controlled environment of a clinical trial. People who spend meaningful time here often move well into regulatory leadership roles, precisely because they understand the full lifecycle of a product rather than just the path to its first approval. If you are early in your career and get the chance to rotate through a post-market or vigilance team, it is worth taking seriously rather than treating as a detour from the core submission work.
Conclusion
The regulatory work that keeps a product safely on the market rarely makes it into a company's launch announcement, but it is where a large and steady share of regulatory affairs careers actually live. If you are evaluating where to specialize, or trying to understand what a role you are interviewing for will really involve, ask specifically about the post-market components, the surveillance obligations, the renewal calendar, the change control process. The answers will tell you a lot about what your weeks will actually look like once the launch celebration is over, and whether the role is a good match for the kind of long-horizon, detail-driven work that keeps a product safely available for the people who depend on it.